Join us for our 2-part series on Long-Acting Injectable (LAI) medications for HIV PrEP. The first session involves an industry talk with two Medical Scientist Liaisons who will share the science and research behind their medications – Lenacapavir and Cabotegravir. This program offers a unique opportunity to engage directly with the industry experts involved in bringing these critical new prevention tools to the forefront of HIV care. The second part will occur on November 11 at 12:00pm and involve a provider panel; the registration link below registers you for both sessions.
Objectives
Upon completion of the first session of this series, participants will be able to:
- Explain the mechanism of action for long-acting injectable medications for HIV PrEP
- Understand the prescribing information for long-acting injectable medications for HIV PrEP
- Summarize clinical trial data that lead to FDA approval of long-acting injectables for HIV PrEP
Intended Audience
- Physicians, Physician Assistants, Nurse Practitioners, Nurses, Pharmacists, Social Workers, Community Health Workers